Wellcome plc

Wellcome plc. Wellcome plc is a global pharmaceutical and biotechnology company headquartered in London, with a significant operational history tracing back to the late 19th century. It is a constituent of the FTSE 100 Index and operates across two core segments: innovative medicines and established pharmaceuticals. The company maintains a major research and development focus in areas including oncology, immunology, and infectious diseases.

History

The company's origins lie in the 1880 partnership between American pharmacists Silas Burroughs and Henry Wellcome, which established Burroughs Wellcome & Co. in London. A pivotal early achievement was the introduction of compressed medicine tablets, a significant innovation over traditional powders. Following Henry Wellcome's death, the Wellcome Trust was established as a charitable foundation, which became the company's majority shareholder for much of the 20th century. Major milestones included the development of AZT for HIV/AIDS treatment and the launch of the anti-flu drug Relenza. The Wellcome Trust divested its final stake in the company in the 1990s, leading to its full public listing on the London Stock Exchange.

Business operations

Wellcome plc's business is divided into two primary global units: Innovative Medicines and Established Pharmaceuticals. The Innovative Medicines unit focuses on research, development, and commercialization of novel therapies, with key research hubs in the United Kingdom, the United States, and Spain. Its Established Pharmaceuticals portfolio includes a wide range of off-patent medicines, particularly strong in emerging markets across Asia, Africa, and Latin America. The company operates a vast global supply chain with manufacturing sites in countries like the United Kingdom, Italy, and Singapore. It also maintains strategic partnerships with academic institutions like the University of Oxford and biotechnology firms such as Genentech.

Corporate governance

The company is governed by a Board of directors chaired by former Australian Prime Minister Julia Gillard, who succeeded John Bell. The CEO is Mark Thompson, formerly of the BBC and The New York Times Company. Key board committees include the Audit Committee, the Remuneration Committee, and the Nomination Committee, which oversee financial reporting, executive pay, and board appointments. The company adheres to the UK Corporate Governance Code and maintains a policy of separating the roles of Chairman and CEO. Senior independent director Susan Kilsby provides additional oversight on governance matters.

Financial performance

For the fiscal year 2023, Wellcome plc reported total revenue of £33.4 billion, with a significant portion derived from its oncology and immunology portfolios. The company's operating profit was £6.1 billion, reflecting continued investment in its R&D pipeline. It is a consistent dividend payer, with a stated policy of returning excess cash to shareholders. Major products contributing to revenue include treatments for rheumatoid arthritis, asthma, and various oncological conditions. The company's financial results are audited by PricewaterhouseCoopers and are significantly influenced by currency fluctuations, particularly the US dollar and the euro.

Corporate social responsibility

The company runs extensive access-to-medicine programs, particularly for neglected tropical diseases in the developing world. It is a signatory to the United Nations Global Compact and has commitments to achieve net-zero carbon emissions across its operations by 2030. Through the legacy of the Wellcome Trust, it maintains historical links to philanthropic funding for biomedical research, though the trust is now a completely separate entity. The company also supports various educational initiatives in STEM fields and partners with organizations like the World Health Organization on disease eradication campaigns.

Controversies

Wellcome plc has faced scrutiny over high drug pricing, particularly in the United States, leading to investigations by the U.S. House Committee on Oversight and Reform. It has been involved in several high-profile product liability lawsuits related to alleged side effects of some of its pharmaceutical products. The company has also settled cases with the U.S. Department of Justice regarding marketing practices and allegations of violating the False Claims Act. Environmental groups have criticized its manufacturing waste disposal practices at certain sites, leading to regulatory actions by the Environment Agency in the UK.